{"prompt": "['PROTOCOL SUMMARY', 'Title:', 'A Phase 3, Randomized, Double-Blind Placebo-Controlled,', 'Multi-Center Study to Assess the Efficacy and Safety of', 'Lumateperone Monotherapy in the Treatment of Patients with', 'Major Depressive Episodes Associated with Bipolar I or Bipolar', 'Il Disorder (Bipolar Depression) Conducted Globally', 'Pr\u00e9cis:', 'This is a Phase 3, randomized, double-blind, placebo-', 'controlled, multi-center study to evaluate the efficacy and', 'safety of lumateperone monotherapy in the treatment of', 'patients with major depressive episodes associated with', 'Bipolar I or Bipolar Il Disorder (Bipolar Depression). The', 'study consists of the following periods: screening period,', 'double-blind on-treatment period, and safety follow-up', 'period.', 'Screening Period (2 Weeks)', 'Potential patients will be evaluated during a screening period', 'lasting up to 2 weeks to ensure sufficient washout of restricted', 'medications. Extension to the screening period may be', 'approved by the Sponsor or representative in extenuating', 'circumstances related to the patient or caregiver.', 'After obtaining written informed consent, diagnostic interviews', 'and physical examinations will be conducted, vital signs and', 'ECGs will be assessed, and blood samples for laboratory', 'assessments will be collected. Patients considered potentially', 'eligible for participation will be required to discontinue their', 'current antidepressant treatment and/or other psychotropic', 'drugs.', 'At baseline (Visit 2 2), patients who continue to meet all eligibility', 'criteria will be randomly assigned in a 1:1 ratio to 1 of the 2', 'treatment arms (60 mg ITI-007 or placebo) for a 6-week,', 'double-blind treatment period.', 'On-Treatment Period (6 Weeks)', 'Patients will take their first dose of study medication the', 'evening of their randomization visit. A single dose will be', 'taken each day in the evening for the duration of the on-', 'Intra-Cellular Therapies, Inc. Confidential', 'xi ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['treatment period. Following randomization, patients will make', 'clinic visits at Days 8, 15, 22, 29, 36 and 43.', 'The on-study treatment period will be a total of 6 weeks.', 'Safety Follow-up Period (2 Weeks)', 'A return to the clinic for a safety follow-up visit will occur at', 'Week 8, approximately 2 weeks following the last dose of', 'study medication. If possible, patients who withdraw', 'prematurely will be seen for an early termination visit (within 1', 'week of early termination) and will be asked to return to the', 'clinic for a safety follow-up visit 2 weeks following their last', 'dose of study medication.', 'Objectives:', 'Primary Objective:', 'The primary objective of this study is to compare the efficacy of', 'lumateperone administered orally once daily to that of placebo', 'as measured by mean change from baseline to Day 43 in the', 'total score on the Montgomery-Asberg Depression Rating', 'Scale (MADRS) in patients with Bipolar Depression.', 'Secondary Objectives:', 'Key Secondary Objective:', 'The key secondary objective of this study is to compare the', 'efficacy of lumateperone administered orally once daily to that', 'of placebo as measured by mean change from baseline to Day', '43 in the total score on the Clinical Global Impression Scale,', 'Bipolar version - Severity (CGI-BP-S) in patients with Bipolar', 'Depression.', 'Intra-Cellular Therapies, Inc. Confidential', 'xii ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['Safety Secondary Objectives:', 'The safety secondary objectives of this study are to determine', 'the safety and tolerability of lumateperone administered orally', 'once daily for 6 weeks in patients with Bipolar Depression,', 'compared to placebo. Safety and tolerability will be assessed', 'in relation to:', 'Incidence of adverse events (AEs);', 'Mean change from baseline in the Young Mania Rating', 'Scale (YMRS);', 'Mean change from baseline in the Columbia Suicide', 'Severity Rating Scale (C-SSRS);', 'Mean change from baseline in the Abnormal Involuntary', 'Movement Scale (AIMS);', 'Mean change from baseline in the Barnes Akathisia', 'Rating Scale (BARS);', 'Mean change from baseline in the Simpson Angus', 'Scale (SAS);', 'Changes from baseline in clinical laboratory evaluations;', 'Changes from baseline in electrocardiograms (ECGs);', 'Changes from baseline in vital sign measurements;', 'Intra-Cellular Therapies, Inc. Confidential', 'xiii ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}